Search Within

Michal Sarfaty

Formats
  1. Meeting Abstract (6)
  2. Journal Article (4)
  3. Review (1)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Weinberg Fellows (8)
  5. Department of Pathology and Laboratory Medicine (7)
  6. GSK Faculty (6)

More Groups

People
  1. Ashley Regazzi (10)
  2. Jonathan Rosenberg (10)
  3. Gopakumar Iyer (8)
  4. Chung-Han Lee (7)
  5. Dean Bajorin (7)
  6. Hikmat Al-Ahmadie (7)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2021 (5)
  4. 2020 (4)
Publications
  1. Journal of Clinical Oncology (7)
  2. Cancer Medicine (1)
  3. Cancers (1)
  4. Clinical Genitourinary Cancer (1)
  5. Current Oncology Reports (1)
Publishers
  1. American Society of Clinical Oncology (7)
  2. Elsevier Inc. (1)
  3. MDPI (1)
  4. Springer (1)
  5. Wiley Blackwell (1)

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Novel genetic subtypes of urothelial carcinoma with differential outcomes on immune checkpoint blockade
    Journal Article

    Sarfaty, M.; Golkaram, M.; Funt, S. A.; Al-Ahmadie, H.; Kaplan, S.; Song, F.; Regazzi, A.; Makarov, V.; Kuo, F.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The cost of enfortumab vedotin wastage due to vial size — A real-world analysis
    Journal Article

    Sarfaty, M.; Moore, A.; Regazzi, A. M.; Mitchell, A. P.; Rosenberg, J. E.
    Cancers (2021)

    Fulltext@MSK | Save
  • Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors
    Meeting Abstract

    Sarfaty, M.; Desjardins, C. A.; Giardina, P.; Bardhan, K.; Pandian, S.; Halley, K.; Halvorsen, E. M.; Callahan, M. K.; Postow, M. A.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Lenis, A. T.; Chen, Z.; Al-Ahmadie, H. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Genitourinary medical oncology expert opinion survey regarding treatment management in the COVID-19 pandemic
    Journal Article

    Sarfaty, M.; Feldman, D. R.; Morris, M. J.; Motzer, R. J.; Rathkopf, D. E.; Regazzi, A. M.; Iyer, G.; Voss, M. H.; Bajorin, D. F.; Rosenberg, J. E.
    Clinical Genitourinary Cancer (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save